Information Provided By: 
Fly News Breaks for May 16, 2018
ALKS
May 16, 2018 | 06:52 EDT
Citi analyst Liav Abraham upgraded Alkermes to Buy with an unchanged price target of $62. The stock closed yesterday down 80c to $46.24. Following a "deep dive" and physician survey, the analyst has increased conviction around the ALKS 3831 value proposition. ALKS 3831 is a once-daily, oral atypical antipsychotic drug candidate for the treatment of schizophrenia. Abraham views Alkermes' valuation as compelling and is positive on the company's "pipeline optionality and near-term catalyst flow."
News For ALKS From the Last 2 Days
